PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. is a U.S.-based biotechnology company focused on developing cellular therapies for cancer using its proprietary Cell-in-a-Box® live-cell encapsulation platform. The company’s current product candidate family includes CypCaps™, with development centered on therapies for pancreatic cancer and other oncology indications.

45.28

12.33

— PharmaCyte Biotech, Inc.
%
Cellular therapy platform70% Encapsulated live-cell technologies designed to activate cancer prodrugs near tumors.
Lead oncology product candidate20% CypCaps™ and related encapsulated-cell product candidates for pancreatic cancer.
Preclinical and translational development10% Research, assay development, and nonclinical work supporting IND-enabling studies.

PharmaCyte Biotech does not currently sell commercial products; its primary counterparties are regulators, clinical...

  • Regulatory authoritiesprimary

    FDA and comparable agencies review INDs, clinical holds, and trial packages for the company's oncology programs.

  • Clinical investigators and trial sitesprimary

    Hospitals, physicians, and research sites conduct preclinical and clinical studies for LAPC and related programs.

  • Potential licensing partnerssecondary

    Large pharmaceutical companies may license approved product candidates for commercialization.

  • Future oncology patientsemerging

    Patients with pancreatic cancer and other cancers would be treated if the therapies reach market.

The company is headquartered in Las Vegas, Nevada and is incorporated in the United States. Its business is primarily U...

  • •Headquartered in Las Vegas, Nevada
  • •Incorporated in Nevada, United States
  • •Primary regulatory exposure is to the FDA and U.S. healthcare laws
  • •Clinical development is centered on U.S.-based oncology programs
  • •Future commercialization could extend to Europe through EMA pathways

The company’s strategy is to advance its Cell-in-a-Box® platform through regulatory clearance and clinical development...

01
Clear the FDA clinical hold on LAPCshort-term

Regulatory clearance is required before the planned pancreatic cancer trial can proceed.

02
Advance the Cell-in-a-Box® oncology platformmedium-term

The platform is the core technology underpinning the company's product candidates.

03
Preserve commercialization flexibilitymedium-term

The company may need a licensing or partnership route to bring any approved therapy to market.

PharmaCyte Biotech faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays,...

high

FDA clinical hold on the LAPC program

The planned pancreatic cancer trial cannot proceed until requested studies and responses are accepted.

Scope
Lead product candidate development
Materiality
high
high

Dependence on SG Austria technology and know-how

The company disclosed that licensed patents have expired and know-how resides with SG Austria.

Scope
Core platform access
Materiality
high
high

Clinical and preclinical failure

Oncology programs may fail to show safety, efficacy, or manufacturability in trials.

Scope
Product candidate pipeline
Materiality
high
high

Dilution and financing risk

The company expects to need additional capital and may rely on equity, debt, or partnerships.

Scope
Corporate funding
Materiality
high
medium

Biologics manufacturing complexity

Cell-based products require specialized facilities, quality controls, and validated processes.

Scope
Cell encapsulation and fill-finish steps
Materiality
medium
medium

Nasdaq listing compliance risk

A sustained low share price could lead to delisting and reduce liquidity for investors.

Scope
Public market access
Materiality
medium
Fair value of financial instruments
Can affect reported gains, losses, and balance sheet values
Impairment of indefinite-lived intangible assets
Can create non-cash charges and reduce asset carrying values
Stock-based compensation
Can materially affect operating expenses and net loss
Related-party service agreements
Requires careful disclosure and expense classification
No revenue and development-stage expense profile
Quarterly comparability is driven by project timing rather than sales seasonality

Vaxcyte, Inc.

PCVX · Biological Products, (No Diagnostic Substances)

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

Unicycive Therapeutics, Inc.

UNCY · Pharmaceutical Preparations

MAXCYTE, INC.

MXCT · Services-Commercial Physical & Biological Research

VERACYTE, INC.

VCYT · Services-Medical Laboratories

HALOZYME THERAPEUTICS, INC.

HALO · Biological Products, (No Diagnostic Substances)

: 29.4.2026